Study on the intestinal mechanism of Jianpi Qushi He Luo Fang in regulating intestinal bacteria AHR agonist host immunity in treating IM
- Conditions
- Idiopathic membranous nephropathy
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Kidney biopsy pathological diagnosis of MN, or positive anti-PLA2R antibody;
(2) Meet the diagnostic criteria of spleen deficiency syndrome;
(3) The course of disease is longer than 6 months;
(4) Urine protein was quantified at 3-8g /24h;
(5) Blood pressure can be effectively controlled at =140/90mmHg;
(6) eGFR 45 ml/min or more,
(7) 18-70 years old, no gender limitation;
(8) Antibiotics and probiotics have not been used in the past one month;
(9) Body mass index (BMI) between 18.5 and 28.5 kg/m2;
(10) Signed informed consent.
(1) Exclude secondary membranous nephropathy (including tumor-related membranous nephropathy, hepatitis B-related membranous nephropathy, lupus membranous nephropathy, drug and toxin-related membranous nephropathy);
(2) the eGFR < 45 ml/min.
(3) hormone and/or immunosuppressant treatment within 6 months;
(4) women who have pregnancy plan, pregnancy or breast-feeding period;
(5) complicated with serious diseases of heart, brain, liver and hematopoietic system, or other serious diseases affecting their survival;
(6) Metabolic diseases such as obesity and diabetes;
(7) History of gastrointestinal diseases or gastrointestinal surgery (except appendectomy);
(8) Rheumatoid arthritis, sjogren's syndrome and other autoimmune diseases;
(9) Antibiotics and probiotics were used within the past one month.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intestinal flora;AHR;Intestinal microbiota metabolites;
- Secondary Outcome Measures
Name Time Method Interleukin;Urine protein quantification at 24 hours;Th17;biochemical;PLA2R;Treg;